Key Highlights
- $10.4 million Series A funding secured to advance RTN-001 for hypertension treatment.
- RTN-001 targets patients with uncontrolled hypertension, demonstrating significant efficacy in prior studies.
- Retension Pharmaceuticals poised to initiate a Phase 2 study, addressing a critical unmet medical need.
Source: Business Wire
Notable Quotes
- “We are thrilled with the close of our first external financing round and incredibly appreciative of the support we have received from Collage Venture Partners and our new investors, many of whom have a deep understanding of our disease areas and the critical need for new and efficacious hypertension treatments.” — Eric Keller, CEO and Co-Founder at Retension Pharmaceuticals
- “Inhibition of PDE5 is a long-desired mechanism for enhancing NO-based signaling for the treatment of hypertension, and I am very pleased to see Retension Pharmaceuticals progress this important new therapeutic option for patients with uncontrolled and resistant hypertension.” — Dr. Jonathan Stamler, Distinguished University Professor at University Hospitals and CWRU
- “With an established mechanism with well-studied safety and tolerability and demonstrated ability to reduce blood pressure on top of standard therapy, RTN-001 is a significantly de-risked experimental therapeutic agent that has the potential to be a paradigm-shifting treatment.” — Dr. Bill Sasiela, Chief Medical Officer at Retension Pharmaceuticals
SoHC's Take
Retension Pharmaceuticals is making significant strides in addressing a major unmet need in hypertension management. The successful closing of its $10.4 million Series A financing not only reflects strong investor confidence but also underscores the potential of RTN-001 as a novel therapeutic option. Given the robust clinical data and a clear regulatory pathway, Retension is well-positioned to make a meaningful impact on the treatment landscape for patients with uncontrolled hypertension. The upcoming Phase 2 study will be crucial in solidifying RTN-001’s role in this space.
